Bank of New York Mellon
ZYNE

Bank of New York Mellon’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Bank of New York Mellon’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-26,311
Closed -$8.58K – 4426
2023
Q2 		$8.58K Sell
26,311
-10,251
-28% -$3.67K ﹤0.01% 4349
2023
Q1 		$15.7K Sell
36,562
-100
-0.3% -$53 ﹤0.01% 4329
2022
Q4 		$19.4K Sell
36,662
-81
-0.2% -$51 ﹤0.01% 4362
2022
Q3 		$27K Buy
36,743
+100
+0.3% +$113 ﹤0.01% 4411
2022
Q2 		$42K Sell
36,643
-70
-0.2% -$89 ﹤0.01% 4385
2022
Q1 		$75K Hold
36,713
– – ﹤0.01% 4459
2021
Q4 		$106K Hold
36,713
– – ﹤0.01% 4394
2021
Q3 		$156K Buy
36,713
+17,056
+87% +$76.1K ﹤0.01% 4256
2021
Q2 		$104K Sell
19,657
-1,895
-9% -$9.11K ﹤0.01% 4213
2021
Q1 		$100K Sell
21,552
-1,902
-8% -$8.62K ﹤0.01% 4166
2020
Q4 		$77K Buy
23,454
+13,288
+131% +$50.5K ﹤0.01% 4112
2020
Q3 		$34K Buy
10,166
+1
+0% +$4 ﹤0.01% 4057
2020
Q2 		$34K Sell
10,165
-53,290
-84% -$252K ﹤0.01% 4022
2020
Q1 		$243K Sell
63,455
-4,546
-7% -$21.1K ﹤0.01% 3678
2019
Q4 		$411K Buy
68,001
+6,544
+11% +$44.8K ﹤0.01% 3687
2019
Q3 		$464K Buy
61,457
+3,159
+5% +$35.6K ﹤0.01% 3577
2019
Q2 		$789K Buy
+58,298
New +$673K ﹤0.01% 3360
2018
Q2 		– Sell
-33,319
Closed -$290K – 4329
2018
Q1 		$290K Buy
33,319
+1,504
+5% +$16.2K ﹤0.01% 3810
2017
Q4 		$398K Sell
31,815
-4,251
-12% -$48.7K ﹤0.01% 3704
2017
Q3 		$301K Buy
36,066
+537
+2% +$5.68K ﹤0.01% 3757
2017
Q2 		$602K Buy
35,529
+23,364
+192% +$465K ﹤0.01% 3516
2017
Q1 		$245K Buy
12,165
+635
+6% +$12.6K ﹤0.01% 3812
2016
Q4 		$180K Buy
+11,530
New +$155K ﹤0.01% 3921
2016
Q3 		– Sell
-10,129
Closed -$69K – 4326
2016
Q2 		$69K Buy
+10,129
New +$84.8K ﹤0.01% 4125

Other funds holding ZYNE

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of New York Mellon's ZYNE Position: Q3 2023 in Review

Bank of New York Mellon sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2023, closing a stake of 26,311 shares — an estimated $8.58K sold.

Bank of New York Mellon first reported a position in ZYNE in Q2 2016 and held it in 24 quarters. The position peaked at $789K in Q2 2019. 43 funds tracked by Wall St. Rank hold ZYNE as of Q3 2023.

  • Bank of New York Mellon reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 26,311 Zynerba Pharmaceuticals, Inc shares in Q3 2023, an estimated $8.58K.
  • Bank of New York Mellon first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2016 and held it in 24 quarters.
  • Bank of New York Mellon's Zynerba Pharmaceuticals, Inc position peaked at $789K in Q2 2019.
  • 43 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2023.

Based on Bank of New York Mellon's 13F filing for Q3 2023, filed 24 Oct 2023.